Radio Free never accepts money from corporations, governments or billionaires – keeping the focus on supporting independent media for people, not profits. Since 2010, Radio Free has supported the work of thousands of independent journalists, learn more about how your donation helps improve journalism for everyone.

Make a monthly donation of any amount to support independent media.





Novo Nordisk’s $50 billion in Ozempic & Wegovy Sales Comes at the Expense of Healthcare Solvency

Novo Nordisk announced its latest earnings to investors today. Ozempic & Wegovy sales now total $49.74 billion since Ozempic’s 2018 launch. Stock buybacks and dividends total $44.38 billion over the same period. Meanwhile, Novo Nordisk’s self-reported…

Novo Nordisk announced its latest earnings to investors today. Ozempic & Wegovy sales now total $49.74 billion since Ozempic’s 2018 launch. Stock buybacks and dividends total $44.38 billion over the same period. Meanwhile, Novo Nordisk’s self-reported research & development investments for the period across its entire portfolio total only $21.33 billion.

On Monday, Public Citizen wrote to U.S. Health and Human Services Secretary Xavier Becerra calling on the government to facilitate generic competition using its authority under existing law. Public Citizen Access to Medicines Director Peter Maybarduk issued the following statement:

“Novo rakes while healthcare breaks. Novo’s outrageous prices force health programs to ration treatment, sacrifice services or both. Novo sells its semaglutide (GLP-1) drugs at more than 100 times the estimated production cost, and with nearly $50 billion in sales, made up its R&D costs in the last few months alone. In fact, Novo’s self-enrichment through stock buybacks and dividends more than doubles the corporation’s entire R&D investments since Ozempic’s launch.”

Separately, North Carolina State Treasurer Dale Folwell wrote to Sec. Becerra last week, urging the federal government to intervene in its unsuccessful efforts to lower GLP-1 drug prices, overcome Novo’s patent monopoly and negotiate generic entry. The Treasurer said if the State Health Plan were to continue to cover weight loss drugs, it would have to double its premiums to families of public employees. It is past time for Novo to cut prices, but Novo has refused, even though state health programs working to serve families have asked time and time again.

Since Novo will not take responsibility, the federal government must, by unlocking generic competition with Novo’s outrageously priced patented drugs.


This content originally appeared on Common Dreams and was authored by Newswire Editor.


Print Share Comment Cite Upload Translate Updates

Leave a Reply

APA

Newswire Editor | Radio Free (2024-08-07T14:52:48+00:00) Novo Nordisk’s $50 billion in Ozempic & Wegovy Sales Comes at the Expense of Healthcare Solvency. Retrieved from https://www.radiofree.org/2024/08/07/novo-nordisks-50-billion-in-ozempic-wegovy-sales-comes-at-the-expense-of-healthcare-solvency/

MLA
" » Novo Nordisk’s $50 billion in Ozempic & Wegovy Sales Comes at the Expense of Healthcare Solvency." Newswire Editor | Radio Free - Wednesday August 7, 2024, https://www.radiofree.org/2024/08/07/novo-nordisks-50-billion-in-ozempic-wegovy-sales-comes-at-the-expense-of-healthcare-solvency/
HARVARD
Newswire Editor | Radio Free Wednesday August 7, 2024 » Novo Nordisk’s $50 billion in Ozempic & Wegovy Sales Comes at the Expense of Healthcare Solvency., viewed ,<https://www.radiofree.org/2024/08/07/novo-nordisks-50-billion-in-ozempic-wegovy-sales-comes-at-the-expense-of-healthcare-solvency/>
VANCOUVER
Newswire Editor | Radio Free - » Novo Nordisk’s $50 billion in Ozempic & Wegovy Sales Comes at the Expense of Healthcare Solvency. [Internet]. [Accessed ]. Available from: https://www.radiofree.org/2024/08/07/novo-nordisks-50-billion-in-ozempic-wegovy-sales-comes-at-the-expense-of-healthcare-solvency/
CHICAGO
" » Novo Nordisk’s $50 billion in Ozempic & Wegovy Sales Comes at the Expense of Healthcare Solvency." Newswire Editor | Radio Free - Accessed . https://www.radiofree.org/2024/08/07/novo-nordisks-50-billion-in-ozempic-wegovy-sales-comes-at-the-expense-of-healthcare-solvency/
IEEE
" » Novo Nordisk’s $50 billion in Ozempic & Wegovy Sales Comes at the Expense of Healthcare Solvency." Newswire Editor | Radio Free [Online]. Available: https://www.radiofree.org/2024/08/07/novo-nordisks-50-billion-in-ozempic-wegovy-sales-comes-at-the-expense-of-healthcare-solvency/. [Accessed: ]
rf:citation
» Novo Nordisk’s $50 billion in Ozempic & Wegovy Sales Comes at the Expense of Healthcare Solvency | Newswire Editor | Radio Free | https://www.radiofree.org/2024/08/07/novo-nordisks-50-billion-in-ozempic-wegovy-sales-comes-at-the-expense-of-healthcare-solvency/ |

Please log in to upload a file.




There are no updates yet.
Click the Upload button above to add an update.

You must be logged in to translate posts. Please log in or register.